Sunmax Biotechnology Co

Sunmax Biotechnology Co R&D per Employee

The R&D Spending per Employee of Sunmax Biotechnology Co (4728.TWO) as of Oct 27, 2026 is 1.14 M TWD. In the previous year, R&D Spending per Employee was 1.06 M TWD — a change of 7.79% (higher).

R&D per Employee

1.14 MTWD

YoY

7.79%

Last updated:

R&D Spending per Employee of Sunmax Biotechnology Co is 2025 1.14 M TWD. R&D Spending per Employee of Sunmax Biotechnology Co was 2024 1.06 M TWD. It decreases by 7.79% higher compared to the previous year.

The Sunmax Biotechnology Co R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
527,216.22 TWD
Jan 1, 2019
611,027.03 TWD
Jan 1, 2020
473,891.89 TWD
Jan 1, 2021
665,648.65 TWD
Jan 1, 2022
485,729.73 TWD
Jan 1, 2023
776,837.84 TWD
Jan 1, 2024
1.06 M TWD
Jan 1, 2025
1.14 M TWD
The Sunmax Biotechnology Co R&D per Employee history
YEARR&D per EmployeeYoY
1.14 MTWD+7.79%
1.06 MTWD+36.31%
776,837.84TWD+59.93%
485,729.73TWD-27.03%
665,648.65TWD+40.46%
473,891.89TWD-22.44%
611,027.03TWD+15.90%
527,216.22TWD+64.96%
319,594.59TWD-39.50%
528,216.22TWD-9.01%
580,540.54TWD-0.46%
583,243.24TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sunmax Biotechnology Co Stock analysis

What does Sunmax Biotechnology Co do? SunMax Biotechnology Co., Ltd. generates revenue through the development, manufacturing, and commercialization of medical devices, biomedical materials, and bio surgical products. Its major products include collagen, collagen implants, microfiber collagen hemostat, collagen absorbable hemostat pads, healthcare products, and medical collagen application equipment. These products are sold to customers in the medical and beauty care industries across Taiwan, Mainland China, and other regions. The company's distribution focuses on these key markets, leveraging its product portfolio for healthcare and aesthetic applications. The firm's product line targets both medical and beauty care sectors, with collagen-based solutions serving as core offerings. Medical collagen application equipment supports clinical procedures, while collagen implants and hemostat products address surgical and wound care needs. The company's presence in Taiwan, Mainland China, and other regions enables it to serve diverse healthcare markets with standardized product offerings. SunMax Biotechnology's revenue streams are derived from the sale of collagen-based medical devices and equipment, with a focus on applications in surgery, wound care, and aesthetic treatments. By distributing its products through established channels in Taiwan, Mainland China, and other regions, the company capitalizes on demand for biocompatible materials in healthcare and beauty care industries. Sunmax Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sunmax Biotechnology Co stock

R&D Spending per Employee of Sunmax Biotechnology Co is 1.14 M TWD in 2025.

R&D Spending per Employee of Sunmax Biotechnology Co changed from 1.06 M TWD to 1.14 M TWD, representing a 7.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Sunmax Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Sunmax Biotechnology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Sunmax Biotechnology Co

All Key Metrics — Sunmax Biotechnology Co